Last updated on RxList: 6/21/2021
Qbrexza Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Qbrexza?

Qbrexza (glycopyrronium) Cloth is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis (sweaty underarms) in adults and pediatric patients 9 years of age and older.

What Are Side Effects of Qbrexza?

Common side effects of Qbrexza include:

  • dry mouth,
  • dilated pupils,
  • mouth pain,
  • sore throat,
  • headache,
  • urinary hesitation,
  • blurred vision,
  • dry nose,
  • dry throat,
  • dry eye,
  • dry skin,
  • constipation, and
  • local skin reactions (redness, burning/stinging and itching)

Dosage for Qbrexza

Dosage of Qbrexza is a single-use cloth pre-moistened with 2.4% glycopyrronium solution. Qbrexza is for topical use in the underarm area only and not for use in other body areas.

What Drugs, Substances, or Supplements Interact with Qbrexza?

Qbrexza may interact with other anticholinergic medications. Tell your doctor all medications and supplements you use.

Qbrexza During Pregnancy and Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using Qbrexza; it is unknown how it would affect a fetus. It is unknown if Qbrexza passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Qbrexza (glycopyrronium) Cloth, 2.4%, for Topical Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Sweat is odorless. See Answer
Qbrexza Professional Information

3 pharmacies near 20147 have coupons for Qbrexza (Brand Names:Qbrexza for 30 Pad)

CVS Pharmacy
CVS Pharmacy

Est. Regular Price


with free coupon

View Coupon

Est. Regular Price


with free coupon

View Coupon

Est. Regular Price


with free coupon

View Coupon


The following adverse reactions are described in greater detail in other sections

  • Worsening of Urinary Retention [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two double-blind, vehicle-controlled clinical trials (Trial 1 [NCT02530281] and Trial 2 [NCT02530294]) of 459 subjects treated with Qbrexza once daily and 232 treated with vehicle, subjects were 9 to 76 years of age, 47% male, and the percentages of White, Black (including African Americans), and Asian subjects were 82%, 12%, and 1%, respectively.

Table 1 summarizes the most frequent adverse reactions (≥2%) in subjects with primary axillary hyperhidrosis treated with Qbrexza.

Table 1: Adverse Reactions Occurring in ≥2% of Subjects

Adverse Reactions Qbrexza
n (%)
n (%)
Dry mouth 111 (24.2%) 13 (5.6%)
Mydriasis 31 (6.8%) 0
Oropharyngeal pain 26 (5.7%) 3 (1.3%)
Headache 23 (5.0%) 5 (2.2%)
Urinary hesitation 16 (3.5%) 0
Vision blurred 16 (3.5%) 0
Nasal dryness 12 (2.6%) 1 (0.4%)
Dry throat 12 (2.6%) 0
Dry eye 11 (2.4%) 1 (0.4%)
Dry skin 10 (2.2%) 0
Constipation 9 (2.0%) 0

Table 2 shows the most frequently reported local skin reactions, which were relatively common in both the Qbrexza and vehicle groups.

Table 2: Local Skin Reactions

Local Skin Reactions Qbrexza
n (%)
n (%)
Erythema 77 (17.0%) 39 (16.9%)
Burning/stinging 64 (14.1%) 39 (16.9%)
Pruritus 37 (8.1%) 14 (6.1%)
a Patients with a post-baseline local skin reaction assessment

In an open-label safety trial (NCT02553798), 564 subjects were treated for up to an additional 44 weeks after completing Trial 1 or Trial 2. Adverse reactions occurring at a frequency ≥2.0% were: dry mouth (16.9%), vision blurred (6.7%), nasopharyngitis (5.8%), mydriasis (5.3%), urinary hesitation (4.2%), nasal dryness (3.6%), dry eye (2.9%), pharyngitis (2.2%), and application site reactions (pain [6.4%], dermatitis [3.8%], pruritus [3.8%], rash [3.8%], erythema [2.4%]).

Read the entire FDA prescribing information for Qbrexza (Glycopyrronium Cloth, 2.4%, for Topical Use)


Dehydration: Causes, Symptoms & Tips to Stay Hydrated See Slideshow

© Qbrexza Patient Information is supplied by Cerner Multum, Inc. and Qbrexza Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors